Association of a miR-502-Binding Site Single Nucleotide Polymorphism in the 3'-Untranslated Region of SET8 and the TP53 Codon 72 Polymorphism with Cervical Cancer in the Chinese Population

  • Yang, Shao-Di (Key Laboratory of Green Packaging and Application of Biological Nanotechnology, Hunan University of Technology) ;
  • Cai, Yan-Lin (Department of Gynecology and Obstetrics, First Hospital Affiliated to Nanhua University) ;
  • Jiang, Pei (Key Laboratory of Green Packaging and Application of Biological Nanotechnology, Hunan University of Technology) ;
  • Li, Wen (Key Laboratory of Green Packaging and Application of Biological Nanotechnology, Hunan University of Technology) ;
  • Tang, Jian-Xin (Key Laboratory of Green Packaging and Application of Biological Nanotechnology, Hunan University of Technology)
  • Published : 2014.08.30


Objective: This study was conducted to identify whether polymorphic variants of set domain-containing protein 8 (SET8) and tumor protein p53 (TP53) codon 72, either independently or jointly, might be associated with increased risk for cervical cancer. Methods: We genotyped SET8 and TP53 codon 72 polymorphisms of peripheral blood DNA from 114 cervical cancer patients and 200 controls using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct DNA sequencing. Results: The frequency of SET8 CC (odds ratios (OR) = 2.717, 95% CI=1.436-5.141) or TP53 GG (OR=2.168, 95% CI=1.149-4.089) genotype was associated with an increased risk of cervical cancer on comparison with the SET8 TT or TP53 CC genotypes, respectively. In additional, interaction between the SET8 and TP53 polymorphisms increased the risk of cervical cancer in a synergistic manner, with the OR being 9.913 (95% CI=2.028-48.459) for subjects carrying both SET8 CC and TP53 GG genotypes. Conclusion: These data suggest that there are significant associations between the miR-502-binding site SNP in the 3'-UTR of SET8 and the TP53 codon 72 polymorphism with cervical cancer in Chinese, and there is a gene-gene interaction.


microRNA;SET8;TP53;polymorphism;cervical cancer;synergism


  1. Abbas T, Shibata E, Park J, et al (2010). CRL4 (Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation. Mol Cell, 40, 9-21.
  2. Akinyemiju TF (2012). Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the world health survey. PLoS One, 7, e48834.
  3. Beck DB, Oda H, Shen SS, Reinberg D (2012). PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation and transcription. Genes & Dev, 26, 325-37.
  4. Bhattacharya P, Sengupta S (2005). Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. Gynecol Oncol, 99, 176-82.
  5. Centore RC, Havens CG, Manning AL, et al (2010). CRL4 (Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase. Mol Cell, 40, 22-33.
  6. Clotti M, Colrtti A, Giuliani L, et al (2006). The p53 codon 72 arg/arg homozygous women in central Italy are at increased risl for HPV infections. Anticancer Res, 26, 3745-8.
  7. Congdon LM, Houstion SI, Veerappan CS, et al (2010). PRSet7- mediated monomethylation of histone H4 lysine 20 at specific genomic regions induces transcriptional repression. J Cell Biochem, 110, 609-19.
  8. Ding C, Li R, Peng J, Li S, Guo Z (2012). A polymorphism at the miR-502 binding site in the 3'untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer. Exp Ther Med, 3, 689-92.
  9. Elkhair MM, Ennaji MM, El Kebbaj R, et al (2010). P53 codon 72 polymorphism and risk of cervical carcinoma in Moroccan women. Med Oncol, 27, 861-6.
  10. Giacomini KM, Brett CM, Aitman RB, et al (2007). The pharmacogenetics research network: from SNP discovery to clinical drug response. Clinical Pharmacology & Therapeutics, 81, 328-45.
  11. Ginsberg GM, Lauer JA, Zelle S, Baeten S, Baltussen R (2012). Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ, 344, e614.
  12. Gocze K, Gombos K, Juhasz K, et al (2013). Unique microRNA expression profiles in cervical cancer. Anticancer Res, 33, 2561-7.
  13. Govan VA, Loubser S, Saleh D, Hoffman M, Williamson AL (2007). No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency. Int J Immunogenet, 34, 213-7.
  14. Guo Z, Wu C, Wang X, et al (2012). A polymorphism at the miR- 502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer, 131, 1318-22.
  15. Habbous S, Pang V, Eng L, et al (2012). P53 Arg72Pro polymorphism, HPV statues and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res, 18, 6407-15.
  16. Hollstein M, Hainaut P (2010). Massively regulated genes: the example of TP53. J Pathology, 220, 164-73.
  17. Houston SI, Mcmanus KJ, Adams MM, et al (2008). Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J Biol Chem, 283, 19478-88.
  18. Jiang P, Liu J, Zeng X, Li W, Tang J (2010). Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women. Cancer Genetics and Cytogenetics, 197, 174-8.
  19. Jogensen S, Elvers I, Trelle MB, et al (2007). The histone methyltransferase SET8 is required for S-phase Progression. J Cell Biol, 179, 1337-45.
  20. Kim T, Lee SY, Rho JH, et al (2009). Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. Mol Cancer Res, 7, 1645-54.
  21. Li Z, Nie F, Wang S, Li L (2011). Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci USA, 108, 3116-23.
  22. Moore EE, Wark JD, Hopper JL, et al (2012). The role of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. Twin Res Hum Genet, 15, 79-86.
  23. Nicoloso MS, Sun H, Spizzo R, et al (2010). Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res, 70, 2789-98.
  24. Oda H, Okamoto I, Murphy N, et al (2009). Monomethylation of histone H4-lysine 20 is involved in chromosome structure and stability and is essential for mouse development. Mol Cell Biol, 29, 2278-95.
  25. Roh JW, Kim BK, Lee CH, et al (2010). P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res, 18, 453-9.
  26. Setteetham-Ishida W, Kanjanavirojkul N, Kularbkaew C, Ishida T (2005). Human papillomavirus genotypes and the p53 codon 72 polymorphism in cervical cancer of Northeastern Thailand. Microbiol Immunol, 49, 417-21.
  27. Shi X, Kachirskaia I, Yamaguchi H, et al (2007). Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell, 27, 636-46.
  28. Shuai HL, Luo X, Yan RL, et al (2012). XRCC1 polymorphisms are associated with cervical cancer risk and response to chemotherapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 6423-7.
  29. Singhal P, Hussain S, Thakur N, et al (2013). Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol, 32, 19-27.
  30. Sitakan N, Wannapa SI, Chamsai P, et al (2013). Human papillomavirus genotypes and cervical cancer in Northeast Thailand. APJCP, 14, 6961-4.
  31. Song F, Zheng H, Liu B, et al (2009). An miR-502-binding site single-nucleotide polymorphism in the 3'-Untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res, 15, 6292-300.
  32. Storey A, Thomas M, Kalita A, et al (1998). Role od a p53 polymorphism in the development of human papillomavirusassciated cancer. Nature, 393, 229-34.
  33. Tardat M, Murr R, Herceg Z, Sardet C, Julien E (2007). PR-Set7- dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol, 179, 1413-26.
  34. Wang C, Guo Z, Li Y, Kang S (2012). A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer. Cancer Genet, 205, 373-6.
  35. Xu J, Yin Z, Gao W, et al (2013). Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS ONE, 8, e77024.
  36. Zhou X, Gu Y, Zhang SL (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a huge review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14.

Cited by

  1. Association between a p73 Gene Polymorphism and Genetic Susceptibility to Non-small Cell Lung Cancer in the South of China vol.15, pp.23, 2015,
  2. Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk vol.37, pp.5, 2016,
  3. Association of codon 72 polymorphism of p53 with the severity of cervical dysplasia, E6-T350G and HPV16 variant lineages in HPV16-infected women vol.66, pp.9, 2017,
  4. gene and cancer risk in Asian populations: a meta-analysis vol.38, pp.6, 2018,